Katy Sutcliffe

Katy Sutcliffe is a medical writer at Oxford PharmaGenesis since April 2022, following an experience as an associate medical writer. Previously, Katy held a research fellowship and postdoctoral research associate position at the University of Bristol, focusing on molecular dynamics simulations and mechanisms related to fentanyl overdose deaths. This fellowship was funded by the European Cystic Fibrosis Society and Cystic Fibrosis Europe. Earlier roles include an internship in molecular pharmacology at Sosei Heptares and a placement at AstraZeneca, where Katy contributed to the assessment of toxicity profiles of DNA damage response inhibitors. Katy earned a PhD in Pharmacology and an MSci in Pharmacology with Study in Industry from the University of Bristol, where education was completed from 2011 to 2019.